Treatment Selection and Monitoring Considerations for Advanced Therapies

Dr. Vachhani discusses balancing thrombotic risk reduction in patients with higher white blood cell counts while implementing newer treatments, asking about selection between ruxolitinib and interferon based on individual patient tolerability. Dr. El Chaer explains that ruxolitinib provides effective hematocrit control, spleen reduction, and symptom improvement, but its immunosuppressive effects require active risk management, particularly in this patient with diabetes and obesity already conferring infection risk susceptibility. JAK inhibition adds to infection risk, necessitating patient counseling about infections, ensuring age-appropriate up-to-date vaccinations including herpes zoster vaccination (now available as inactivated vaccine), and maintaining low thresholds for febrile illness evaluation.

Non-melanoma skin cancer surveillance becomes very important with long-term ruxolitinib use, as demonstrated in myelofibrosis experience, leading to annual dermatology referral incorporation into monitoring plans. From cardiovascular standpoints, thrombotic risk does not completely disappear with cytoreduction, so aspirin continuation remains important, with cardiovascular teams staying closely engaged for blood pressure, lipid, and glycemic management. The therapeutic balance involves sufficient immunosuppression to control PV disease while managing iatrogenic effects from prescribed medications. Busulfan and other alkylating agents are avoided given leukemogenic risk and high cytopenia risk.

Regarding interferon therapy considerations, Dr. El Chaer monitors for autoimmune diseases that can develop during interferon therapy including thyroiditis, hepatitis, and colitis. Monitoring includes thyroid-stimulating hormone levels at least twice yearly, lipid panels twice yearly focusing on triglycerides, questioning about arthralgias suggesting rheumatoid arthritis development, baseline ophthalmologic examination for retinal assessment, and ophthalmology referrals for vision changes. Interferon can cause cytopenias including lymphopenia and neutropenia, typically manageable with dose reduction. Interferon therapy can itself cause pruritus, managed with antihistamines rather than aspirin (unlike aquagenic pruritus), sometimes requiring dose reduction. Liver function monitoring is essential as interferon can cause transaminitis.

Dr. Vachhani emphasizes key differences between treatment modalities: interferons require injections while ruxolitinib represents oral twice-daily pills. Personalized management becomes crucial when selecting between different cytoreductive therapies for individual patients. He considers interferon more as first-line management for newly diagnosed patients over hydroxyurea due to disease-modifying activity, applicable regardless of age. Newer interferons like ROPEG interferon alfa-2b enable dosing even in patients in their 80s with careful monitoring. In second-line settings, particularly for splenomegaly or symptom management beyond hematocrit or phlebotomy requirement control, ruxolitinib provides excellent symptom control alongside JAK2 allele burden reduction achieved with both interferon and ruxolitinib therapies.